Yimiao Li

Dr. Yimiao Li


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2025 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
BMBin Ma
Bin Ma
YLYimiao Li
Yimiao Li
TWTinghui Wang
Tinghui Wang
DLDongming Li
Dongming Li
SJShuang Jia
Shuang Jia
As an important class of microorganisms, filamentous fungi have crucial roles in protein secretion, secondary metabolite production and environmental pollution control. However, characteristics such as apical growth, heterokaryon, low homologous recombination (HR) efficiency and the scarcity of genetic markers mean that the application of traditional gene editing technology in filamentous fungi faces great challenges. The introduction of the RNA-mediated CRISPR/Cas (clustered regularly interspaced short palindromic repeat/CRlSPR-associated protein) system in filamentous fungi in recent years has revolutionized gene editing in filamentous fungi. In addition, the continuously expressed CRISPR system has significantly improved the editing efficiency, while the optimized sgRNA design and reduced cas9 concentration have effectively reduced the off-target effect, further enhancing the safety and reliability of the technology. In this review, we systematically analyze the molecular mechanism and regulatory factors of CRISPR/Cas9, focus on the optimization of its expression system and the improvement of the transformation efficiency in filamentous fungi, and reveal the core regulatory roles of HR and non-homologous end-joining (NHEJ) pathways in gene editing. Based on the analysis of various filamentous fungi applications, this review reveals the outstanding advantages of CRISPR/Cas9 in the enhancement of protein secretion, addresses the reconstruction of secondary metabolic pathways and pollutant degradation in the past decade, and provides a theoretical basis and practical guidance for the optimization of the technology and engineering applications.

24 August 2026 in npj Vaccines
Verified
Journal Article
Open access
PDF file
YZYang Zang
Yang Zang
JFJian Feng
Jian Feng
YPYutong Peng
Yutong Peng
WCWei Cui
Wei Cui
WWWenzhe Wang
Wenzhe Wang
Wei HuWei Hu
Wei Hu
Alveolar echinococcosis (AE) is a life-threatening zoonotic disease caused by the larval stage of Echinococcus multilocularis (E. multilocularis). It is characterized by the tumor-like invasive growth pattern and limited treatment options. Although immunoprophylaxis represents a promising strategy, it is difficult to achieve sufficient immune activation without disrupting Th1/Th2 immune homeostasis. Here we report a cage-assembled antigenic particle vaccine (CAP-V) that leverages a self-assembling protein nanocage to elicit protective antiparasitic immunity. CAP-V is constructed using an engineered circularly permuted E2 (CPE2) scaffold to display the full-length E. multilocularis 14-3-3 antigen through either genetic fusion or post-assembly SpyCatcher–SpyTag conjugation. Both vaccine sequence formulations assemble into homogeneous nanoparticles and can be efficiently produced in Escherichia coli. Mechanistically, CAP-V induced BMDC maturation-associated responses and coordinated cellular and humoral immunity. In vivo immunization elicited concurrent Th1- and Th2-associated responses, with a comparatively stronger IFN-γ/IgG2c-associated component. Importantly, this coordinated immune profile is associated with significant protection against E. multilocularis challenge, reflected by reduced parasite burden and ameliorated tissue pathology. Together, these findings demonstrate Em14-3-3 CAP-Vs as a modular and mechanistically informed protein nanovaccine platform and highlight its potential for immunoprophylaxis against AE and other chronic helminthic diseases.